EMA Reviews Oxbryta: Therapy Would Be 1st in EU Targeting SCD Root Cause

EMA Reviews Oxbryta: Therapy Would Be 1st in EU Targeting SCD Root Cause

284516

EMA Reviews Oxbryta: Therapy Would Be 1st in EU Targeting SCD Root Cause

The European Medicines Agency (EMA) is reviewing an application from Global Blood Therapeutics (GBT) that seeks full marketing approval for the oral therapy Oxbryta (voxelotor) for people with sickle cell disease (SCD), ages 12 and up. Oxbryta would be the first treatment targeting the root cause of SCD, hemolytic anemia, to be approved in the EU. “We look forward to working with the EMA to meet our goal of bringing the first treatment for hemolytic…

You must be logged in to read/download the full post.